[EN] INHIBITORS OF FARNESYL PROTEIN TRANSFERASE<br/>[FR] INHIBITEURS DE LA FARNESYL-TRANSFERASE
申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:WO1997030992A1
公开(公告)日:1997-08-28
(EN) This invention relates to compounds that inhibit farnesyl-protein transferase and ras protein farnesylation, thereby making them useful as anti-cancer agents. The compounds are also useful in the treatment of diseases, other than cancer, associated with signal transduction pathways operating through ras and those associated with proteins other than ras that are also post-translationally modified by the enzyme farnesyl protein transferase. The compounds may also act as inhibitors of other prenyl transferases, and thus be effective in the treatment of diseases associated with other prenyl modifications of proteins.(FR) La présente invention concerne des composés inhibant la farnésyl-transférase et la farnésylation de la protéine Ras, ce qui en fait d'utiles agents anticancéreux. Ces composés conviennent également particulièrement au traitement de maladies autres que le cancer, associées aux canaux de transduction de signaux par la protéine Ras, et de maladies associées à des protéines autres que les protéines Ras qui subissent une modification post-translationnelle sous l'effet de la farnésyl-transférase. Ces composés se comportent également comme inhibiteurs d'autres prényl-transférases, et peuvent de ce fait convenir au traitement d'affections associées à d'autres modifications prényl des protéines.
FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS
申请人:Ahmed Gulzar
公开号:US20090221555A1
公开(公告)日:2009-09-03
The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R
1
, R
2
, R
3
, R
4
, R
5
, A
1
, A
2
, A
3
, A
4
, and A
5
, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors
申请人:Ahmed Gulzar
公开号:US20120165519A1
公开(公告)日:2012-06-28
The present invention provides a compound of formula I or II
or a pharmaceutically acceptable salt form thereof, wherein R
1
, R
2
, R
3
, R
4
, R
5
, A
1
, A
2
, A
3
, A
4
, and A
5
, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.